METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to control advanced prostate cancer
Disease control Recruiting nowThis study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New combo therapy aims to control advanced prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer that has spread. The main goal is to check safety and side effects, while also measuring h…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New prostate cancer combo aims to outperform standard therapy
Disease control Recruiting nowThis phase 3 trial tests whether a new drug called rezvilutamide, combined with hormone therapy, works better than the current standard enzalutamide plus hormone therapy for men with low-volume metastatic hormone-sensitive prostate cancer. About 206 participants will receive one …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Could drug holidays ease fatigue in advanced prostate cancer?
Disease control Recruiting nowThis study tests whether men with metastatic hormone-sensitive prostate cancer who have a very low PSA can safely take breaks from hormone therapy (relugolix) to reduce fatigue. Half the participants will take the drug continuously, the other half will take breaks. The study will…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New hope for prostate cancer: adding surgery or radiation to drug therapy may delay progression
Disease control Recruiting nowThis study is for men with metastatic hormone-sensitive prostate cancer that has spread to a limited number of sites. Participants first receive standard drug therapy (apalutamide plus hormone therapy) for 6 months, then are randomly assigned to either continue drug therapy alone…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: NA • Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
Massive prostate cancer registry aims to map Real-World treatment patterns
Knowledge-focused Recruiting nowThis study is a long-term registry that will follow 5000 men with prostate cancer that has come back or spread. It includes four groups: men with a rising PSA after initial treatment, those whose cancer resists hormone therapy but hasn't spread, those with newly spread cancer, an…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated May 17, 2026 02:14 UTC
-
New study tracks Real-World safety of triple therapy for Low-Volume prostate cancer
Knowledge-focused Recruiting nowThis study looks at medical records of 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are taking darolutamide plus standard hormone therapy and chemotherapy. Researchers want to see how safe the combination is and how well it controls the cancer…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC
-
New study tracks brain and body side effects of prostate cancer drugs
Knowledge-focused Recruiting nowThis study follows 102 men with advanced prostate cancer to see how their thinking, energy, mood, and sleep change during treatment with hormone therapy plus newer targeted drugs. Participants fill out questionnaires at the start, 3 months, and 6 months. The goal is to understand…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC